secwatch.observer — SEC 8-K summary
======================================

Issuer:     Elanco Animal Health Inc (ELAN)
CIK:        0001739104
Form:       8-K
Filed at:   2022-11-08T23:59:59+00:00
Accession:  0001104659-22-115672
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elanco Q3 revenue $1,028M, net loss $49M; cuts FY 2022 guidance on FX and macro headwinds
--------------------------------------------------------------------------------

- Q3 revenue down 9% reported (4% constant currency) to $1,028M; pet health fell 11%, farm animal down 7%.
- Reported EPS $(0.10); adjusted EPS $0.20 (up 5% YoY); adjusted EBITDA $205M (19.9% margin, +120bps).
- FY 2022 revenue guidance lowered to $4,385-4,430M (from $4,465-4,550M); adjusted EPS cut to $1.01-1.07 from $1.06-1.13.
- Net leverage ratio 5.2x; $170M gross debt reduction in Q3; cash flow from ops $189M vs $89M YoY.
- Pipeline: FDA submission for broad-spectrum parasiticide; SGLT-2 feline diabetes drug and parvovirus mAb expected approvals by early 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1739104/000110465922115672/0001104659-22-115672-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1739104/000110465922115672/tm2229803d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-115672

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer